Support from readers like you keeps The Journal open.
You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.
If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.
THE END OF the year is fast-approaching and pharmaceutical companies and scientists have been working flat-out all through 2020 to develop a safe and effective vaccine for the virus that causes Covid-19.
Health officials have said the roll-out of a vaccine is the only thing that can ensure a full return to the normality people knew before this pandemic. Although the research is by no means complete, there is a strong sense of optimism in the medical and scientific community about the prospect of a vaccine in 2021.
Dr Fidelma Fitzpatrick, consultant and senior lecturer in microbiology at the Royal College of Surgeons (RCSI) has said the speed of pace in this race for a vaccine has been “amazing”.
“It normally takes between five to 10 years to bring a vaccine to market,” she told TheJournal.ie. “Usually one of the biggest hurdles can be funding, which doesn’t seem to be an issue now. Other issues can be manufacturing, logistics and scaling up. But it all starts in the lab with scientists in the pre-clinical stages.
“There is a huge amount of pre-clinical work before it gets to clinical trials – cell culture and animal testing before moving to tests on human. Most vaccine candidates stop at this point.”
After the pre-clinical stage and before a vaccine can be manufactured, it goes through three phases of clinical trials.
Phase One involves between 20 and 100 volunteers and the intention is to establish whether the vaccine is safe, whether it seems to work and whether there are any serious side effects. This phase will also look at how the size of the dose may be related to side effects.
Phase Two will involve several hundred people and aims to establish the most common short-term side effects and how the immune systems of those who have been given the vaccine respond.
Phase Three is the most crucial and the most thorough. It involves hundreds of thousands of people, some of whom will be given a placebo.
This phase examines how people who get the vaccine compared with those who get the placebo, whether it is safe and/or effective and it also aims to catch less common side effects as it involves a larger – and ideally more diverse – pool of people.
The results of the the trials go straight to regulators for examination after Phase Three and if the vaccine is approved based on the results, it can begin to be manufactured and administered.
The World Health Organisation has said 44 candidate vaccines are in clinical evaluation with 10 of those at the Phase Three clinical stage. These are:
Sinovac, an inactivated vaccine, requires two doses;
Siopharm/Wuhan Institute of Biological Products, an inactivated vaccine, requires two doses;
Sinopharm/Beijing Instituate of Biological Products, an inactivated vaccine, requires two doses;
University of Oxford/AztraZeneca, a non-replicating viral vector vaccine, requires one dose;
CanSino Biological Inc/Beijing Institute of Biotechnology, a non-replicating viral vector vaccine, requires one dose;
Gamaleya Research Institute, a non-replicating viral vector vaccine, requires two doses;
Janssen Pharmaceutical Companies (Johnson & Johnson), a non-replicating viral vector vaccine, requires two doses;
Novavax, a protein sub-unit vaccine, requires two doses;
Moderna/NIAID, an RNA vaccine, requires two doses;
Pfizer/BioNTech/Fosun, an RNA vaccine, requires two doses.
Some methods for making a vaccine are tried-and-true, while others remain experimental.
Inactivated ‘classic’ vaccines use a virus germ that has been killed or a weakened or “attenuated” strain that is virulent enough to provoke antibodies but not to cause disease. Other inactivated vaccines include polio, hepatitis A and rabies.
Viral vector varieties use other forms of live virus to deliver DNA into human cells, triggering an immune response. A measles virus modified with a coronavirus protein, for example, could be deployed against Covid-19.
The Johnson & Johnson vaccine uses a dose of a cold-causing adenovirus, modified so that it can no longer replicate. This is combined with a part of the new virus, SARS-CoV-2, called the spike protein that it uses to invade human cells.
‘Sub-unit’ vaccines, such as the Novacvax one, contain a fragment of the pathogen that it is derived from to produce an appropriate immune response. Other examples include the HPV and hepatitis B vaccines.
There are also experimental gene-based vaccines using DNA or RNA fragments.
How the trials are progressing
Results from many of these initial phases are encouraging, but until Phase Three data from these vaccines is published, it is too early to tell which ones could be used en masse.
Advertisement
Preliminary results from Sinpharm‘s trials, published in The Lancet journal, show it provoked an immune response. The company has said it anticipates antibodies from its jab to last between one and three years.
Recently the Sinovac vaccine, even though it hasn’t been approved for mass market distribution, was made available to some residents in an eastern Chinese city. Officials said the vaccine would be given to people aged between 18-59 with “urgent needs”. The vaccine requires two doses, given up to 28 days apart. The company has also already completed construction of a vaccine factory able to produce 300 million doses a year.
In September, trials on the coronavirus vaccine developed by AstraZeneca and Oxford University were paused after a UK volunteer developed an unexplained illness. The vaccine is one of the most advanced Western projects, having already been tested on tens of thousands of volunteers worldwide. British regulators and an independent review concluded the illness was not a side effect of the vaccine.
Trials resumed earlier this month in Japan but not the United States, where AstraZeneca is working with regulators. This week it was confirmed that a volunteer participating in clinical trials of the vaccine developed by Oxford University had died, but the man had received a placebo, rather than the active vaccine. The Phase Three trial is continuing.
During the summer, China’s military approved the CanSino vaccine for use within its ranks. Pakistan regulators also approved Phase Three testing for this vaccine in the country’s first ever clinical trial of this kind. However this vaccine uses a weakened human cold virus, adenovirus 5, and the Phase Two trial found high pre-existing immunity to this cold virus in participants reduced the immune response.
The Russian vaccine, developed by Gamaleya Research Institute, has already been used to vaccine high-profile Russians, including President Vladamir Putin’s daughter. Patients in early trials involving 76 people all developed antibodies, according to research published in The Lancet medical journal last week, while experts said the trials were too small to prove safety and effectiveness.
The Johnson & Johnson trial was paused recently over safety concerns after one patient became sick. Its Phase Three had started recruiting participants in September with a goal of enrolling up to 60,000 people. Pre-clinical testing on rhesus macaque monkeys that were published in the journal Nature showed it provided complete or near-complete protection against virus infection in the lungs and nose.
The US firm Novavax, which uses insect cells to grow synthesised pieces of the spike protein of the SARs-CoV-2 virus. Its early trials found the vaccine was well-tolerated and elicited robust antibody responses. The company has said it proved the efficacy of a flu vaccine using this same technology.
Initial results from Moderna‘s trials indicate those who receive the vaccine produce antibody reactions from T-cells (a type of white blood cell). The company recently said it had successfully recruited ethnic minorities, older people and those with underlying conditions for its Phase 3 trial as it works to “develop a vaccine for everyone, including communities that have historically been under-represented”. It is aiming to file for authorisations soon after 25 November.
The Pfizer vaccine’s first two phases showed it produces antibodies and T-cell responses specific to the coronavirus protein. It has said it will apply for emergency authorisation in the US in late November if safety data pans out.
Optimistic
Dr Fitzpatrick said the pace at which these vaccines have been developed has been “remarkable” and she is optimistic about the development of a safe vaccine.
“It can take nearly 10 years to complete a vaccine and we have 10 of them at Phase Three already so that has to be cause for optimism.
“It’s so unprecedented, in October to have this number of candidates, anything can happen. Once we get to one or more being approved, the big question is where do you start? And how do you compare different trials? The WHO is now looking at trying to harmonise the methodology for vaccine makers to better facilitate that. We need to be able to compare like with like.
“Once we get that sorted we’re looking at the global distribution issues. Who do we prioritise, which areas of the world, which groups of people? How do we ensure we don’t overwhelm the cold chain? Because they have to be transported in fridges.”
She said it is likely that the first people to receive the vaccine will be healthcare workers and those in high-risk groups. However she said people should bear in mind that they will likely have to keep going with infection control measures for some time.
“The whole world isn’t going to get it at once,” she said. “This isn’t the be all and end all.”
“We will still have unknowns, like how long does it last and what we do in terms of people who just don’t respond to the vaccine, but there are other options such as giving monoclonal antibodies that might be open approach down the road.”
Fitzpatrick said she acknowledges some people may be wary of getting a new vaccine – and one that has been developed so quickly.
Knowledge is power here. I always say to people to go and read the facts for themselves, go to reliable sources to inform yourself when you’re making a decision.
“There has never been a time when the entire world has been so focused on one type of vaccination programme so there will be huge scrutiny of the safety of these vaccines. The whole point of the Phase Three trials is to find any rare side effects that wouldn’t come through in the Phase One and Two trials.
“This isn’t going to get a free pass, there’s too much to lose, the entire world is looking at it so the regulators aren’t just going to push things through.”
- With reporting from AFP.
Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article.
Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.
TheJournal.ie's Coronavirus Newsletter
TheJournal.ie's coronavirus newsletter cuts through the misinformation and noise with the clear facts you need to make informed choices. Sign up here
To embed this post, copy the code below on your site
Close
78 Comments
This is YOUR comments community. Stay civil, stay constructive, stay on topic.
Please familiarise yourself with our comments policy
here
before taking part.
@Charlie Hebdo:
the sun is not freedom of press it is rupert murdoch and the belief system. There is a huge difference between cutting edge analysis and insulting, lazy and vindictive journalism.
@Charlie Hebdo: freedom of the press to insult and incite a whole community through disgusting narrow minded racist and elitist articles? Absolutely.
And in turn we should all exercise our right to boycott this sensationalist braindead rag of pure tripe.
Agreed?
@Charlie Hebdo: Did I say they should be closed down or anything like that? No I said that people/individuals should make the choice to boycott the rag. The more that boycott them the less viable their business model.
@Charlie Hebdo: You’re looking for drama where there is none. If I had said that the paper should be shut down, you would have a valid point but I’m afraid you will have to find your drama elsewhere today. People/ organisations being encouraged to ban/boycott is not censorship!!
@Charlie Hebdo: Using “Freedom of the Press” as a means of defending The Sun is an insult to real journalists who risk their lives or livelihoods to report the truth. This guy was a glorified troll looking to insult and degrade people for the sake of it.
If you can’t see the difference you are an utter fool.
@Charlie Hebdo: And Charlie was responsible for the deaths of so many innocents including his own workers and I am sure in the KKK.English Defence League HQ MacKenzie is a true patriot.
@Charlie Hebdo: I think you’re wilfully missing the point in order to soap-box. No one’s calling for The Sun to be banned. Simply Everton FC are availing of their own right to reply and offering a rebuttal. That they, a private company, are choosing not to engage with another private company whose practices they fundamentally disagree with, is hardly tantamount to shutting down the press.
@Charlie Hebdo: Some of the most thought provoking and enlightening journalism comes from points of view I disagree with. This article was neither of those things. What exactly has this guy added to the public discourse with this article? It’s trash and people have every right to voice their criticism without being accused of harming the freedom of the Press.
@Fergal O’ Reilly: ” No one’s calling for The Sun to be banned” . . . The OP called for it to be banned and that is what my original comment was responding to. also Everton have banned the newspaper.
@Charlie Hebdo: Maybe you struggle with basic language but if you would like to re-read my original comment you will find that I did not call for the Sun to be banned. I said that people and organisations should make that decision. If I had said that “the sun should be closed down or banned” you would have a very valid point but it’s obvious that you are just grandstanding for the sake of it.
@Charlie Hebdo:
Wow charlie, you really are going all out to defend the sun. How on Earth did you find yourself in such an unenviable position. The sun paper is in no way being censored or discouraged from printing its tripe, EFC have simply decided that they don’t want the suns product on their private property. Like a children’s food store might choose not to sell rat poison on their shelves. But all of this has already been explained to you, but you seem unwilling or unable to process sensible explanations or arguments. You seem dogged in your defence of one of the most disgusting papers ever to go to print. Are you proud of yourself? Is anyone proud of you?
@Soccer T’s:
And I’m pointing out to him that the freedom of the press is not being attacked here. This is a different matter all together. He is confusedly arguing that EFC’s actions towards the sun constitutes an attack on the free press. This is not the case, and if he felt so passionately about the freedom of press why not comment on an article about vladimir putin rather then defend the sun so vigorously.
@Soccer T’s: Labour Party and Tory party should be treated like sc€m for this and the other covers ups.
Don’t have anything against British people but their government are consistently awful.
How you can trust a government to do good abroad when they even have such disdain for their own people.
The double standards in the press here w.r.t British parties is galling.
@Soccer T’s: best selling paper in England and the sun is printed in Knowsley in Liverpool so as to boycotting it not all Liverpool is so you all wasting your time just get over yourself and move on , great paper buy it everyday.
@Alan Lawlor: A bit of an ill informed comment. Everton football club and supporters have ALWAYS shown solidarity with LFC in the fight for justice for the 96 fans that died at Hillsborough. https://youtu.be/Nmzu29eRhMU
Haven’t read that rag in years. The article was published to upset Liverpudlians on the eve of the anniversary of the Hillsborough tragedy and does not surprise me one little bit. The editor should be fired for publishing it and the author should be shot for….just being himself.
I thought the sun was a great news paper. Both it and the Daily mail are often only a euro. Which is a quarter the price of smoke pellets for testing newly installed stoves. I honestly used to buy them for that until I realised I was supporting them by buying it, so now I pay more for another news paper just to burn.
I automatically assume that anyone who gathers their information from outlets like the sun, daily mail, etc. are buffoons whose opinion should be ignored at all costs.
@Charlie Hebdo: what he wrote was nothing got to do with sports journalism. Allowing these views are more dangerous. We have a right to free press alright but not the opinion and ramblings of a spiteful hateful person.
@Joe Travers: in other words Joe you just disagree/dislike his views and want them suppressed, freedom of the press should apply to all news outlets not just the ones you like or agree with.
@Charlie Hebdo: dangerous precedent my ar$e. You’re still living in the 70s are ya when journalists actually reported News rather than deliberately incite hatred, persecute and vilify persons of their own choosing and sensationalise tragic stories.
In fact small gestures like this might actually prompt editors to be more responsible in their reporting.
Unlikely though.
@Charlie Hebdo: Err just to educate you, Kelvin Mc Kenzie the author of the offending article, is not a sports journalist.It must be dizzy up on your high horse.
It may be a loathsome publication but I think a complete ban on it or its employees sets a dangerous precedent. Sanitised news/reporting only results in dumbed down information.
The paper is a rag, it must be said, and that phrase, “Any publicity is good publicity.”, makes me think they won’t care one bit about all this, and might actually be secretly delighted their paper is in the news.
Video shows 15 aid workers killed in Gaza were in marked vehicles - contradicting Israel’s account
Updated
1 hr ago
6.4k
Horse Racing
Nick Rockett crowned Aintree Grand National champion in 1-2-3 for Willie Mullins
Updated
26 mins ago
2.9k
14
trade war
China slaps extra 34% tariffs on US imports as Trump vows his 'policies will never change'
Updated
4 Apr
62.3k
186
Your Cookies. Your Choice.
Cookies help provide our news service while also enabling the advertising needed to fund this work.
We categorise cookies as Necessary, Performance (used to analyse the site performance) and Targeting (used to target advertising which helps us keep this service free).
We and our 164 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting Accept All enables tracking technologies to support the purposes shown under we and our partners process data to provide. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Cookie Preferences link on the bottom of the webpage .Your choices will have effect within our Website. For more details, refer to our Privacy Policy.
We and our vendors process data for the following purposes:
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.
Cookies Preference Centre
We process your data to deliver content or advertisements and measure the delivery of such content or advertisements to extract insights about our website. We share this information with our partners on the basis of consent. You may exercise your right to consent, based on a specific purpose below or at a partner level in the link under each purpose. Some vendors may process your data based on their legitimate interests, which does not require your consent. You cannot object to tracking technologies placed to ensure security, prevent fraud, fix errors, or deliver and present advertising and content, and precise geolocation data and active scanning of device characteristics for identification may be used to support this purpose. This exception does not apply to targeted advertising. These choices will be signaled to our vendors participating in the Transparency and Consent Framework.
Manage Consent Preferences
Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then these services may not function properly.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not be able to monitor our performance.
Store and/or access information on a device 111 partners can use this purpose
Cookies, device or similar online identifiers (e.g. login-based identifiers, randomly assigned identifiers, network based identifiers) together with other information (e.g. browser type and information, language, screen size, supported technologies etc.) can be stored or read on your device to recognise it each time it connects to an app or to a website, for one or several of the purposes presented here.
Personalised advertising and content, advertising and content measurement, audience research and services development 146 partners can use this purpose
Use limited data to select advertising 116 partners can use this purpose
Advertising presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type or which content you are (or have been) interacting with (for example, to limit the number of times an ad is presented to you).
Create profiles for personalised advertising 85 partners can use this purpose
Information about your activity on this service (such as forms you submit, content you look at) can be stored and combined with other information about you (for example, information from your previous activity on this service and other websites or apps) or similar users. This is then used to build or improve a profile about you (that might include possible interests and personal aspects). Your profile can be used (also later) to present advertising that appears more relevant based on your possible interests by this and other entities.
Use profiles to select personalised advertising 85 partners can use this purpose
Advertising presented to you on this service can be based on your advertising profiles, which can reflect your activity on this service or other websites or apps (like the forms you submit, content you look at), possible interests and personal aspects.
Create profiles to personalise content 39 partners can use this purpose
Information about your activity on this service (for instance, forms you submit, non-advertising content you look at) can be stored and combined with other information about you (such as your previous activity on this service or other websites or apps) or similar users. This is then used to build or improve a profile about you (which might for example include possible interests and personal aspects). Your profile can be used (also later) to present content that appears more relevant based on your possible interests, such as by adapting the order in which content is shown to you, so that it is even easier for you to find content that matches your interests.
Use profiles to select personalised content 35 partners can use this purpose
Content presented to you on this service can be based on your content personalisation profiles, which can reflect your activity on this or other services (for instance, the forms you submit, content you look at), possible interests and personal aspects. This can for example be used to adapt the order in which content is shown to you, so that it is even easier for you to find (non-advertising) content that matches your interests.
Measure advertising performance 136 partners can use this purpose
Information regarding which advertising is presented to you and how you interact with it can be used to determine how well an advert has worked for you or other users and whether the goals of the advertising were reached. For instance, whether you saw an ad, whether you clicked on it, whether it led you to buy a product or visit a website, etc. This is very helpful to understand the relevance of advertising campaigns.
Measure content performance 61 partners can use this purpose
Information regarding which content is presented to you and how you interact with it can be used to determine whether the (non-advertising) content e.g. reached its intended audience and matched your interests. For instance, whether you read an article, watch a video, listen to a podcast or look at a product description, how long you spent on this service and the web pages you visit etc. This is very helpful to understand the relevance of (non-advertising) content that is shown to you.
Understand audiences through statistics or combinations of data from different sources 76 partners can use this purpose
Reports can be generated based on the combination of data sets (like user profiles, statistics, market research, analytics data) regarding your interactions and those of other users with advertising or (non-advertising) content to identify common characteristics (for instance, to determine which target audiences are more receptive to an ad campaign or to certain contents).
Develop and improve services 84 partners can use this purpose
Information about your activity on this service, such as your interaction with ads or content, can be very helpful to improve products and services and to build new products and services based on user interactions, the type of audience, etc. This specific purpose does not include the development or improvement of user profiles and identifiers.
Use limited data to select content 37 partners can use this purpose
Content presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type, or which content you are (or have been) interacting with (for example, to limit the number of times a video or an article is presented to you).
Use precise geolocation data 47 partners can use this special feature
With your acceptance, your precise location (within a radius of less than 500 metres) may be used in support of the purposes explained in this notice.
Actively scan device characteristics for identification 27 partners can use this special feature
With your acceptance, certain characteristics specific to your device might be requested and used to distinguish it from other devices (such as the installed fonts or plugins, the resolution of your screen) in support of the purposes explained in this notice.
Ensure security, prevent and detect fraud, and fix errors 93 partners can use this special purpose
Always Active
Your data can be used to monitor for and prevent unusual and possibly fraudulent activity (for example, regarding advertising, ad clicks by bots), and ensure systems and processes work properly and securely. It can also be used to correct any problems you, the publisher or the advertiser may encounter in the delivery of content and ads and in your interaction with them.
Deliver and present advertising and content 100 partners can use this special purpose
Always Active
Certain information (like an IP address or device capabilities) is used to ensure the technical compatibility of the content or advertising, and to facilitate the transmission of the content or ad to your device.
Match and combine data from other data sources 73 partners can use this feature
Always Active
Information about your activity on this service may be matched and combined with other information relating to you and originating from various sources (for instance your activity on a separate online service, your use of a loyalty card in-store, or your answers to a survey), in support of the purposes explained in this notice.
Link different devices 55 partners can use this feature
Always Active
In support of the purposes explained in this notice, your device might be considered as likely linked to other devices that belong to you or your household (for instance because you are logged in to the same service on both your phone and your computer, or because you may use the same Internet connection on both devices).
Identify devices based on information transmitted automatically 91 partners can use this feature
Always Active
Your device might be distinguished from other devices based on information it automatically sends when accessing the Internet (for instance, the IP address of your Internet connection or the type of browser you are using) in support of the purposes exposed in this notice.
Save and communicate privacy choices 69 partners can use this special purpose
Always Active
The choices you make regarding the purposes and entities listed in this notice are saved and made available to those entities in the form of digital signals (such as a string of characters). This is necessary in order to enable both this service and those entities to respect such choices.
have your say